Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WHAT ABOUT A SAFE SUPPLY OF CBD? One sign we’re living in the darkest timeline: every so-called “expert” on safe supply ignores the double-blind, randomized, placebo-controlled study showing how CBD reduces cravings for opioids.
If “safe supply” was genuinely safe and compassionate, they’d be handing out CBD capsules, not hydromorphone.
Instead, governments like to downplay the dangers of opioids and crank up the drug war on cannabis.
Nothing says we’re living in the darkest timeline like an out-of-control health bureaucracy freaking out about cannabis edibles but turning a blind eye to teens taking heroin-strength opioids.
We’ve demonstrated the public health crusade against cannabis ad nauseam. Whether it’s the economic illiterate calling for limits on THC or the busybodies making unsubstantiated claims about cannabis and mental health.
The messaging from the government is clear: they’d rather have you on opioids than cannabis.
When we exchange cannabis outside the legal regime, it’s “diversion,” and proceeds go to “organized crime.” When taxpayer-funded opioids are illegally distributed and sold, it’s “compassionate sharing.”
WE ARE IN THE DARKEST TIMELINE – EXCISE TAXES & PARDONS HELP NO ONE IN TODAY’S TIME Another sign we’re in the darkest timeline is Joe Biden. I suppose I should expand on that, but I think “Let’s Go, Brandon” pretty much sums it up.
We’ve covered how his federal cannabis pardons help no one. But that hasn’t stopped the senior citizen from repeating the lie. One wonders if the old man truly believes he set people free.
Of course, three years into the Biden presidency, Americans are no closer to cannabis legalization. They can’t even pass banking legislation, negatively affecting Canadian cannabis companies.
Considering that Donald Trump signed the 2018 Farm Bill that legalized all minor cannabinoids, including delta-8 THC, one could easily make the case Trump did more for cannabis legalization than Biden.
In fact, if 2024 is Biden vs. Trump again, and Trump wants to win, he needs to point to the billions spent in Ukraine and ask why the Democrats didn’t spend that domestically.
As well as legalize cannabis.
But don’t legalize the way the Canadians did. As reported by MjBizDaily, Canada’s taxman is getting aggressive with cannabis excise debts.
As we’ve reported, Canada’s cannabis excise tax was designed by morons. It’s systemically bankrupting all the small-to-medium producers. Even the larger ones are losing money. But they can at least weather the storm.
Only in the darkest timeline does Canada Revenue Agency collect so much in taxes that they bankrupt the business they’re taxing.
It takes a special kind of stupidity to work for the government. https://cannabislifenetwork.com/3-signs-were-living-in-the-darkest-timeline/
Hahahahaha good one! Have had "stinky fingers" for decades. Apparently that is.
We all have our ways on promised land quest.
Agree on the company and bravo zulu to you on your wagers. Averaged down again this morning at 3.94 new cost basis of 6.42 which really is not stuck at all if were to compare with those really stung as if from African bees.
Just sucks to average down buying when apparently bottoming and is not the bottom. Have a finger on the trigger like many more wish a bell would ring loud and clear about that but never does. On the flip side when laws change cant wait for shorts to do the reciprocal by averaging up in denial.
Big-time cannabis player Trulieve hits a limit in Massachusetts (Editorial)
Published: Jun. 03, 2023, 4:29 p.m.
When sharing bad news, big companies mask blunders with jargon. We saw that last week when Trulieve, one of the country’s largest cannabis operators, said it would pull out of Massachusetts, shuttering its massive Holyoke growing facility.
Time to focus on “cash preservation,” its CEO said. Time to trim “non-contributive assets.”
Translation: Trulieve is bleeding money after investing more than $33 million in its 56 Canal St. plant.
The Republican’s Jim Kinney reported in February that 2023 would be a year of reckoning for commercial cannabis. Here and there, small-scale retailers had already bottomed out.
Trulieve’s flight from the Bay State adds an exclamation point. The golden age of legal weed is in the books, five years after the debut of adult use sales. Early players, like NETA in Northampton, had it good. Later arrivals have struggled amid falling prices – down from around $400 an ounce in early 2021 to $171 today, according to state officials.
In business lingo, that’s called “price compression.” It leaves cannabis companies subject to the pressures that bedevil all retailers.
For investors, risks brought rewards, to be sure. Gross sales since 2018 have topped $4.6 billion – and are still going strong, with $600 million so far this year, about $28 million a week.
Trulieve made its own mistakes. An employee told Kinney the Holyoke plant was so massive – 600,000 square feet of growing floor – it could have supplied the entire state market. One problem with that, and it’s a big one: Producers under current rules cannot ship outside the state.
That worker is one of 128 who lost jobs last week; the company closed retail stores Saturday in Northampton, Framingham and Worcester.
Trulieve’s $30 million buildout in Holyoke was an overreach. Early word is that the site could sit on the market for a while.
Don’t cry for Trulieve. Though it is also scaling back in California and Nevada, the Canadian company continues operating in Arizona, Connecticut, Florida, Georgia, Maryland, Pennsylvania and West Virginia. Nationally, as laws loosen, the cannabis market will grow.
The cannabis reckoning in Massachusetts will continue, especially as new shops open in Connecticut, New York and Vermont.
In its press releases, Trulieve boasts that it “delivers optimal customer experiences” and helps patients and customers “live without limits.”
The company found, at considerable expense, that limits exist.
If you purchase a product or register for an account through one of the links on our site, we may receive compensation
https://www.masslive.com/opinion/2023/06/big-time-cannabis-player-trulieve-hits-a-limit-in-massachusetts-editorial.html
Pulling out of Mass is good. I'd pull out of any state whose courts rule cannabis dust from grinding flower kills ya.
They also know this but dont talk about it. https://www.statnews.com/2023/05/30/cali-sober-marijuana-opioid-alcohol-addiction/
The phenomenon of being “Cali sober” is taking the recovery world by storm. It is defined as dedicating oneself to a life free of drugs and alcohol — except for cannabis and other psychedelics. (Though many consumers don’t think of cannabis as a psychedelic, policy experts often consider it one because of its effects.)
Hardcore proponents of abstinence-based recovery, such as Alcoholics Anonymous, dismiss the Cali sober approach as dangerous and “not really recovery.” Those who make their livings by treating addiction the traditional ways, such as addiction specialists and representatives of our country’s sprawling rehab industry, also dismiss the idea. For example, the Cleveland Clinic maintains a blanket ban on physicians certifying patients for medical cannabis for any condition (even though medical cannabis is legal in Ohio). One of their addiction psychiatrists told the clinic’s website, “After all, you’re not sober if you’re still using mind-altering substances. You’re replacing one addictive substance with another. It’s a slippery slope.”
But the slippery slope holds no water. I am 15 years into recovery from a vicious addiction to prescription opioids. I’m also a physician and have had the privilege of treating thousands of patients for substance use disorders, ranging from doctors surreptitiously snorting oxycodone to people living on the streets. Through these experiences, I’ve given a great deal of thought to the issues surrounding what predisposes one to addiction, what constitutes an addiction, how we get addicted, and how we recover. The best definition of addiction that I’ve heard, to date, is a simple one, “continued use, despite negative consequences.”
Yet this definition raises some crucial questions: Continued use of what? All drugs, or just the one(s) that derailed your life? For how long? For life?
For nearly a century, the recovery community has largely followed a line from Alcoholics Anonymous: that recovery means abstinence from all drugs and alcohol, completely and forever (except, of course, for tobacco and caffeine, which are considered “good drugs” and are freely allowed at 12-step meetings).
Unfortunately, this binary and ideological approach has an extremely low success rate — by one estimate, 5%-10% for AA. Its rigidity alienates many and is mainly based on historical tradition rather than science. It has very little to do with our modern understanding of addiction, the new treatments we are developing, or the realities that our understandings and treatments of addiction have greatly evolved since the “Big Book” of Alcoholics Anonymous was written in 1939.
It’s time to update that thinking. It isn’t cheating to use medicines or other substances to maintain recovery. In fact, anyone who wants to enter and stay in recovery mainly must find a way to eschew the continued use of the specific drug that derailed your life in a way that is causing ongoing distress.
My definition is more consistent with current scientific thinking about recovery, which includes the use of modern, lifesaving medications that help people overcome the biological components of their addictions. My definition is also more inclusive, and humane. Offering a bigger recovery tent allows more people to feel welcome and safe. This can save lives.
There is no firm scientific basis for the “abstinence only” models of recovery, which have engendered generations of slogans and platitudes that people like me have had to repeat over and over, when forced into rehab, as I was for 90 days. We sat in a group and chanted, “one is too many and a thousand is never enough” as a totem against future drug and alcohol use. This experience, to me, was so boring and mindless; it was enough to make you want to use drugs again.
Moreover, this approach is about as far away from science as one can get on planet Earth. The most convincing study I found, published in JAMA in 2014 showed the opposite:
“As compared with those who do not recover from an SUD [substance use disorder], people who recover have less than half the risk of developing a new SUD. Contrary to clinical lore, achieving remission does not typically lead to drug substitution, but rather is associated with a lower risk of new SUD onset.”
In other words, the tools, insight, and experiences you gain from the process of getting into recovery from one addiction can be protective against other addictions, so one may be at less risk with a different drug than an addiction naive person might be. None of this is definitively settled, but it is intriguing and certainly is consistent with the use of alternative treatments — such as cannabis and psychedelics — to maintain and support one’s recovery.
It is important to state that 12-step programs are quite effective for a self-selected group of people who enjoy these meetings, who relate to them culturally, and who find them invaluable to sustain their recoveries. If someone chooses abstinence, and it works for them, that is something to be supported and celebrated. Yet, there is no rationale or evidence to impose this model on all people seeking recovery.
The first public challenge to abstinence-only recovery paradigms came with widespread adoption of methadone and Suboxone (buprenorphine) to treat opioid use disorder. In short order, stories started filtering out about people being hassled at 12-step meetings for using Suboxone or methadone. People were told at recovery meetings, “you aren’t really in recovery if you are taking methadone/Suboxone – you’re just swapping one drug for another.” I’ve seen people say things along these lines at Narcotics Anonymous meetings. Yet the clinical utilization of Suboxone and methadone results in a 50% reduction in both overdosages and death from overdose. Recovery has to be about the outcomes and about saving and improving lives.
What happens when you go a step further, beyond Suboxone and methadone, and not only challenge the abstinence-only model, but challenge it with medicines/drugs that have been deliberately stigmatized by the war on drugs, such as cannabis and other psychedelics? To many 12-steppers and addiction psychiatrists, the inclusion of cannabis — a “bad” drug — in any talk of “recovery” from addiction is heresy. It bucks against the decades of inaccurate messaging we’ve been given that cannabis is highly addictive and extremely dangerous. It can be difficult for them to understand the idea of Cali sober because many don’t have lived or clinical experience treating people with cannabis, and don’t have a realistic, nuanced view of the relative benefits and harms of cannabis use. They have only been exposed to magnified versions of the harm and have been shielded from discussions of benefits.
We are in the process of a vast societal reevaluation of the relative benefits and harms of cannabis, with public acceptance of both medical and recreational use growing yearly. Using medicinal cannabis to transition away from more dangerous drugs, such as alcohol or heroin, is an increasingly popular and accepted form of harm reduction. I have had tremendous success in my clinical practice transitioning people from both medicinal opioids and alcohol to cannabis. I find cannabis to be particularly efficacious, because it can help treat or palliate many of the symptoms that may have helped incite and fuel the addiction to these other drugs in the first place, such as anxiety, insomnia, chronic pain, and trauma.
It is important to note that cannabis certainly is not without its own set of harms. Cannabis use is best avoided by teenagers (due to the concern about the health of their developing brains), by women who are pregnant or breastfeeding (due to concerns about effects on the fetus/newborn), before driving, or in patients with a personal or family history of psychosis (as cannabis can destabilize these patients). But the best way to prevent use by people who are at risk is careful regulation and education rather than through criminalization, which drives drug use underground and makes it, on the whole, vastly more dangerous.
In no particular order, the critical components of a healthy, stable recovery from addiction are insight, humility, connection, mindfulness, and gratitude. As we focus on the present, connect with others, and approach the world with kindness and humility, we are happier and stronger, and this leaves much less room for the drugs to settle back in.
These are exactly the traits within us that cannabis helps foster, which is why it so powerfully aligns with the personal recovery plans of so many recovering people. To quote the astronomer Carl Sagan, the smartest person I’ve ever met to date (and longtime friend of my father, an academic who was early to challenge popular myths about cannabis):
“The illegality of cannabis is outrageous, an impediment to full utilization of a drug which helps produce the serenity and insight, sensitivity and fellowship so desperately needed in this increasingly mad and dangerous world.”
Related: Psilocybin shows promise for treating alcohol addiction, new study finds
It’s notable this language so thoroughly overlaps the language in the 12-step programs, which are fundamentally based on “serenity and insight, sensitivity and fellowship.”
If people have surmounted their addictions and are back to work, healthy, and living fulfilling, meaningful lives, what does it matter if they are abstinent, on cannabis, using Suboxone, or microdosing with psychedelics? One may yearn for a perfect world in which we would all do yoga, eat tofu, and meditate, where no one feels the need to rely on a drug or a substance to help get us through the day. Yet, there are very few, if any, societies that have existed without the use of one psychoactive drug or another.
Addiction is a deadly consequence of an ugly confluence of distress and drug use that needs to be addressed with empathy, compassion, and evidence, not with judgment, stigma, and adherence to old beliefs that aren’t borne out by research. Every path out of addition and into safe, stable recovery is unique to the person walking it. But all of us who are recovering from addiction nourish and support one another, not to be divided along lines of rigid approaches and inflexible ideologies.
Peter Grinspoon, M.D., is a primary care physician and a cannabis specialist at Massachusetts General Hospital and an instructor in Medicine at Harvard Medical School. He is the author of the new book “Seeing Through the Smoke: A Cannabis Expert Untangles the Truth about Marijuana.”
You bought the sector in which way please?
Florida took the election away from Al Gore will do the same with cannabis, watch law makers then celebrate with alcohol and drive drunk and get away with it.
Her husband is in law enforcement and approves of prohibition, vote her and her husband out.
05-01-2023 New research from the University of Colorado Boulder has revealed that cancer patients who use cannabis to alleviate their symptoms not only experience less pain and improved sleep, but also exhibit an unexpected benefit: clearer thinking.
The findings, published in the journal Exploration in Medicine, represent a significant development in understanding the potential benefits of over-the-counter cannabis for relieving cancer symptoms and chemotherapy side-effects.
“When you’re in a lot of pain, it’s hard to think. We found that when patients’ pain levels came down after using cannabis for a while, their cognition got better,” explained study senior author Professor Angela Bryan.
This small yet groundbreaking study is among the first to investigate the impact of cannabis purchased at dispensaries rather than government-supplied or synthetic cannabis.
In recent years, a growing number of cancer patients have turned to cannabis as a legal option for managing symptoms in most states. Survey data indicates that up to 40 percent of U.S. cancer patients use cannabis; however, only a third of doctors feel comfortable advising patients on its use.
How the study was done
The complexity of studying cannabis is due in part to federal law, which prohibits university researchers from possessing or distributing cannabis for research unless it’s government-issued or of pharmaceutical grade.
Consequently, previous studies have predominantly focused on prescription products like nabilone or dronabinol (typically prescribed for nausea) or government cannabis strains that tend to be less potent and lack the variety of over-the-counter offerings.
To overcome these limitations, Bryan and her research team collaborated with oncologists at the CU Anschutz Medical Campus, observing 25 cancer patients who used cannabis over a two-week period.
After assessing the participants’ pain levels, sleep patterns, and cognition in a baseline appointment, they were instructed to purchase an edible product of their choice from a dispensary.
The choices were surprisingly diverse, spanning 18 brands, with options such as chocolates, gummies, tinctures, pills, and baked goods, and containing various ratios of THC and CBD at a wide range of potencies.
The range of products chosen by the participants highlights the willingness of people to try different options in search of relief, but a lack of data leaves them without guidance on which product works best for their needs.
“This tells us that people are open to trying whatever they think might be useful, but there’s just not much data out there to guide them on what works best for what,” said Bryan.
The researchers behind the study went to great lengths to collect accurate data, using a “mobile laboratory” (a Dodge Sprinter van, sometimes referred to as the “cannavan”) to conduct physical and cognitive assessments at each patient’s home. This allowed the researchers to test the patients before and after using cannabis in their own homes, minimizing external factors that could affect the results.
What the researchers discovered
In the short term, the study found that cannabis use provided significant pain relief within an hour, but also impaired patients’ cognition and made them feel “high” (with higher THC content resulting in a stronger high).
However, after two weeks of consistent use at the patients’ chosen frequency, a different pattern emerged. Participants reported improvements in pain, sleep quality, and cognitive function, with some objective measures of cognitive function, such as reaction times, also showing improvement.
Professor Bryan expressed surprise at the results. “We thought we might see some problems with cognitive function,” she said, noting that both cannabis and chemotherapy have previously been associated with impaired thinking. “But people actually felt like they were thinking more clearly.”
The researchers also found that the more a patient’s pain subsided, the more their cognition seemed to improve. Additionally, those who ingested more CBD, a known anti-inflammatory, reported bigger improvements in sleep quality and pain intensity.
While the findings are preliminary and larger controlled studies are needed, they raise an intriguing possibility: while certain forms and dosages of cannabis for pain relief may impair thinking in the short term, some regimens could potentially improve cognition in the long run by reducing pain.
Personal experience included in the study
Professor Bryan, who had been studying cancer prevention for years and had just begun researching medicinal cannabis use when she was diagnosed with breast cancer in 2017, personally used cannabis to help ease her pain after surgery and chemotherapy.
“The doctors were so supportive of what I wanted to do, but they had no idea what to tell me,” she said. “There was just no data.”
Concerned about using opioids, Bryan created her own custom regimen of more potent THC-heavy products when the pain was intense and she could sacrifice some mental sharpness, and milder, CBD-heavy products to keep the pain manageable. She was not pain-free but managed to avoid using opiates during her treatment.
“I was extremely lucky because I had some knowledge about this. Most patients don’t,” she said. Bryan hopes that her research and future studies will help people make better-informed decisions about using cannabis to manage the symptoms of cancer and its treatments.
As the field of cannabis research continues to expand, these findings provide a valuable insight into the potential benefits of over-the-counter cannabis for cancer patients, and may serve as a foundation for future studies on this topic.
More about cannabis and pain relief
Cannabis has long been used for its pain-relieving properties, and with the growing acceptance and legalization of medicinal cannabis in many parts of the world, research into its therapeutic effects has increased. The two primary active compounds in cannabis, THC (tetrahydrocannabinol) and CBD (cannabidiol), have been shown to have varying effects on pain management.
THC is the psychoactive compound responsible for the “high” experienced when using cannabis. It binds to CB1 receptors in the brain, which are part of the endocannabinoid system, a complex cell-signaling system that plays a role in regulating various physiological processes, including pain perception.
By binding to these receptors, THC can modulate pain signals and provide relief from different types of pain, such as neuropathic pain (associated with nerve damage) and inflammatory pain.
CBD, on the other hand, is a non-psychoactive compound that does not produce a “high.” It is believed to have anti-inflammatory, analgesic (pain-relieving), and neuroprotective properties.
CBD interacts with various receptors in the endocannabinoid system and other neurotransmitter systems, such as serotonin and vanilloid receptors, to modulate pain perception. Research has shown that CBD can be effective in managing conditions like arthritis, multiple sclerosis, and neuropathic pain.
Combining THC and CBD in varying ratios can offer different therapeutic effects, depending on the type and intensity of pain. Some studies suggest that the combination of THC and CBD can provide greater pain relief than either compound alone, due to a phenomenon called the “entourage effect.”
This concept proposes that the various compounds in cannabis work together synergistically to enhance their therapeutic effects.
It’s important to note that the ideal ratio of THC and CBD for pain relief can vary from person to person, and the optimal dosage depends on factors such as the individual’s tolerance, the severity of the pain, and the specific condition being treated. Medical professionals and researchers are still working to determine the most effective formulations and dosages for different types of pain.
In conclusion, cannabis has shown promise as an alternative or supplementary treatment for pain relief in various conditions. However, more research is needed to establish standardized guidelines for its use and to fully understand the long-term effects of cannabis-based therapies.
Always consult a healthcare professional before using cannabis for pain management, as they can help determine the most appropriate treatment plan based on individual needs and circumstances.
https://www.earth.com/news/cannabis-may-be-a-highly-effective-treatment-for-cancer-patients/
Or this fresh news? https://www.stocktitan.net/news/TCNNF/trulieve-announces-georgia-s-first-medical-cannabis-n8g0g04ire73.html
April 27, 2023 - 12:05 pm
New dispensary in Macon provides first patient access to medical cannabis in the state
TALLAHASSEE, Fla., April 27, 2023 -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the grand opening of Georgia's first medical cannabis dispensary in Macon. The new dispensary will be open 10 AM - 7 PM, seven days a week and is located at 3556 Riverside Dr.
Georgia’s first medical cannabis dispensary in Macon, GA will be open 10 AM - 7 PM seven days a week and is located at 3556 Riverside Dr.
Trulieve will host a grand opening celebration on Friday, April 28 at 9:30 AM with a ribbon cutting, food trucks and merchandise giveaways.
The Company will open three more dispensaries this year located at:
Columbus: 4238 Armour Road
Newnan: 1690 E Hwy 34
Pooler: 2002 Pooler Parkway
"We believe that access to medical cannabis improves lives, and Trulieve is proud to be the first to provide that access to the state of Georgia," said Kim Rivers, CEO of Trulieve. "We look forward to providing high quality products and an elite experience."
For more information on how to become a registered patient in Georgia and to sign-up for updates, please visit www.trulieve.com/how-to-get-medical-marijuana-card/georgia.
This is why, it is Elon Musk's new policy relaxing rules on twitter.
https://www.benzinga.com/markets/cannabis/23/04/32045314/twitters-cannabis-ad-revolution-continues-elon-musk-gives-nod-to-packaged-weed-products
Several months after allowing CBD and THC product ads on its site, Twitter has updated its policy yet again. It will now permit accredited advertisers to include packaged cannabis products in their advertisement visuals.
"Going forward, certified advertisers may feature packaged cannabis products in ad creative," Twitter posted on its website.
Until now, cannabis advertisers have been prohibited from illustrating products in their ads nor advocating sales. However, Twitter CEO Elon Musk apparently decided to take cannabis advertising to another level.
As such, cannabis advertisers can responsibly link to their owned and operated web pages and e-commerce experiences for CBD, THC and cannabis-related products and services, Twitter noted.
The latest update comes two weeks after Alexa Alianiello (Twitter US Sales & Partnerships) and Rohan Routroy (Twitter NEXT) joined other top cannabis CEOs, entrepreneurs and advocates at the Benzinga Cannabis Capital Conference in Miami Beach, April 11-12, 2023 as featured keynote speakers.
"Twitter has your back," Alianiello told the packed room at the Fontainebleau Miami Beach Hotel. "We're a part of this community. We're with you on this journey."
This was the first time Twitter had met with cannabis industry executives to discuss the role the social networking giant will play in the marijuana industry, being the first platform to open the door to cannabis advertising.
https://fortune.com/2023/04/27/elon-musk-marijuana-weed-advertising-twitter-420-jokes/
Twitter under its 420-friendly owner Elon Musk earlier this year became the first major social media company to allow cannabis advertisements. Now, the platform is relaxing those rules in an attempt to lure in more advertisers from U.S. states where marijuana is legal.
“Going forward, certified advertisers may feature packaged cannabis products in ad creative,” Twitter said in a post on its website. Previously, cannabis advertisers could not show any products in their ads, nor could they actually promote their sale.
“They may also continue responsibly linking to their owned and operated web pages and e-commerce experiences for CBD, THC, and cannabis-related products and services,” Twitter said.
The billionaire Tesla CEO has been forced to make huge cost cuts and scramble to find more sources of revenue to justify his $44 billion purchase of Twitter. The platform also removed a ban on political advertisements in January.
Still, companies interested in advertising cannabis products on Twitter must comply with a long list of rules. They must be licensed and pre-authorized by Twitter, only target jurisdictions where they are licensed and refrain from targeting anyone under 21, among other policies.
Facebook parent Meta, Google and other major tech companies all prohibit cannabis ads. Google does allow ads for FDA-approved CBD products and topical, hemp-derived CBD products with THC content of 0.3% or less in California, Colorado, and Puerto Rico, but not for marijuana even in states where it is legal.
Musk became widely associated with marijuana usage in 2018 when he tweeted that he was mulling a buyout of Tesla for $420 per share – a price that was widely assumed to be tied to a specific time in the afternoon of April 20 when cannabis users annually celebrate the drug by partaking in it. Shortly after that August 2018 tweet, Musk smoked a marijuana joint on a podcast with Joe Rogan.
In a trial centered on whether Musk’s buyout tweet had misled Tesla investors, Musk testified the price of his offer wasn’t meant to be a marijuana reference while acknowledging why people might think it was.
“There is some, I think, karma around 420. I should question whether that is good or bad karma at this point,” Musk said on the witness stand.
The origins of the term “420” generally, were long murky. Some claimed it referred to a police code for marijuana possession or that it arose from a Bob Dylan song.
Yes indeed, Darth like many others is dismayed at the lack of leadership as if no one is concerned in congress going with status quo of prohibition in light of states like Texas who incarcerate disabled vets for smoking eating vaping herb. Is a conspiracy as the biggest drug pushers in the world are the pill companies. Thats the Cartel!
A Republican congressional committee chairman is demanding that the Food and Drug Administration (FDA) turn over documents relating to the agency’s decision not to regulate CBD products.
Rep. James Comer (R-KY), chair of the House Oversight and Accountability Committee, sent a letter to FDA Commissioner Robert Califf on Monday, announcing an investigation into the agency’s decision and criticizing the “insufficient rationale for inaction” on CBD regulations.
FDA said in January that, after years of review since hemp and its derivatives like CBD were legalized under the 2018 Farm Bill, it determined that there is not a regulatory pathway in place to enact rules allowing the non-intoxicating cannabinoid to be marketed as a food item or dietary supplement. It said that congressional action is required to develop CBD regulations.
Prior to that announcement, Comer had pledged to confront FDA over the lack of regulations for cannabidiol in his capacity as Oversight Committee chairman.
“CBD is an increasingly popular product among adults and has seen an uptick in usage in recent years,” the letter to Califf says, adding that the World Health Organization (WHO) has found CBD to be generally safe and well-tolerated.
“As science is catching up regarding the safety of CBD usage, it is imperative that the FDA recognize its role in regulating these products,” he wrote. “The lack of regulation of non-intoxicating CBD products have allowed for potentially dangerous products to enter the market in the form of Delta-8 and other hemp-derived intoxicants, leading to increasing concern that some products contain potentially dangerous ingredients due to the lack of regulation.”
“Proper regulation from the FDA would not only prevent bad faith actors from entering the market but will increase the amount of good faith manufacturers’ contributions of a useful product for the American public,” Comer said.
He added that the agency’s argument that there’s not a regulatory pathway to enact CBD regulations is an “insufficient rationale for inaction” that is “directly affecting the welfare of the American public.”
“Without allowing for therapeutic CBD products to be regulated as dietary supplements such as melatonin or fish oils, the good faith actors in the industry are unable to enter the market and provide people with helpful products because they are currently not distinguished under the FDA from the intoxicating products containing Delta-8. It is imperative that the FDA engages in this regulation quickly, safely, and efficiently to provide proper guidance to the American people about the safety of CBD products.”
The chairman listed “documents and information” that he’s asking FDA to provide to the committee by May 1:
1. All documents, communications, and drafts related to the January 26 announcement titled “FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward.”
2. All documents and communications relating to the FDA’s assessment of the existing regulatory framework at issue regarding CBD.
3. All scientific data, reports, and research in the possession of the FDA relating to the safety of CBD products for consumption.
Another GOP congressman, Rep. Andy Harris (R-MD), has similarly blasted FDA over the lack of CBD regulations, telling the commissioner in a committee hearing last month that the inaction is “disrupting public confidence” in its abilities.
Top officials in the agency have previously signaled that they felt it may take work from Congress to adequately regulate CBD.
At a House Appropriations subcommittee hearing last year, Califf recognized that the agency had moved slowly with rulemaking for CBD in the food supply, stating that the situation “looks pretty much the same in terms of where we are now” as compared to when he first worked on the issue in 2016.
He said the FDA has taken steps to research the safety profile of cannabinoids to inform future rules, but he also punted the criticism about inaction to Congress, saying he doesn’t feel that “the current authorities we have on the food side or the drug side necessarily give us what we need to have to get the right pathways forward.”
“We’re going to have to come up with something new,” Califf said. “I’m very committed to doing that.”
There have been repeated efforts by congressional lawmakers to fill the regulatory gap for the non-intoxicating cannabinoid.
For example, Reps. Morgan Griffith (R-VA) and Angie Craig (D-MN) reintroduced a pair of bills last month meant to provide a pathway for the regulation of hemp derivatives like CBD as dietary supplements and food and beverage additives.
https://www.marijuanamoment.net/congressional-committee-launches-investigation-into-fdas-decision-not-to-regulate-cbd/
One thing longs should do to support the share price is to hold shares in a cash account so cannot be borrowed and shorted.
Margin accounts allow shares to be borrowed.
POLITICSNew Bipartisan Congressional Bills Would Allow Hemp Derivatives Like CBD As Dietary Supplements And Food Additives
https://www.marijuanamoment.net/new-bipartisan-congressional-bills-would-allow-hemp-derivatives-like-cbd-as-dietary-supplements-and-food-additives/
Bipartisan congressional lawmakers have refiled a pair of bills meant to provide a pathway for the regulation of hemp derivatives like CBD as dietary supplements and food and beverage additives.
The two measures that were filed on Friday—the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act and the CBD Product Safety and Standardization Act—are being sponsored by Reps. Morgan Griffith (R-VA) and Angie Craig (D-MN).
Earlier versions of the bills were filed last Congress and ultimately did not advance, but advocates and industry stakeholders feel that the Food and Drug Administration’s (FDA) recent announcement that it wouldn’t be taking steps to regulate CBD will put pressure on lawmakers to act this time around.
FDA “has dragged its feet in properly regulating CBD and hemp-derived products on the market, creating confusion about its legal uses,” Griffith said in a press release on Friday. “Americans need better guidance and that is why I have introduced these two pieces of legislation, which will create a pathway for regulation in both the food and dietary supplement spaces.”
The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act would mandate that hemp, hemp-derived CBD and other derivatives from the federally legal cannabis plant would be made lawful as dietary supplements under the Federal Food, Drug, and Cosmetic Act (FDCA).
The CBD Product Safety and Standardization Act, meanwhile, would require FDA to develop rules and hold a public comment period on the maximum amount of hemp-derived CBD that could be added to a food item or beverage per serving, labeling and packaging requirements and the “conditions of intended use,” the text of the legislation states.
“In Minnesota we’ve seen firsthand that our local governments and small businesses need more guidance when it comes to CBD and hemp-derived products,” Craig said. “That’s why I’ve partnered with Rep. Griffith on these bipartisan bills to better regulate CBD products, keep consumers safe and ensure our hemp farmers and businesses have the support they need.”
FDA announced in January that it would not be creating rules to allow the marketing of CBD as dietary supplements or food items, leaving the massive industry without regulations despite repeated calls for administrative action from lawmakers, advocates and stakeholders.
Following a “careful review” of the non-intoxicating cannabinoid, FDA said it reached the conclusion that the existing regulatory pathways that are in place for other dietary supplements and food additives will not work for CBD. Instead, the agency said that wants to “work with Congress on a new way forward.”
“The FDA has made it clear that legislative action by Congress is needed to solve its CBD regulatory problem and these two bi-partisan bills re-introduced by Reps. Griffith and Craig serve as the solution,” U.S. Hemp Roundtable General Counsel Jonathan Miller said in a press release. “The FDA’s inaction over the past four years has had a devastating impact on U.S. hemp growers, and has left thousands of unregulated products on the marketplace, raising health and safety concerns for consumers.”
FDA’s announcement came days after the agency released finalized guidance that focuses on developing cannabis-based drugs and outlined the process and unique considerations for scientists when it comes to hemp and marijuana.
Meanwhile, House Oversight and Accountability Committee Chairman James Comer (R-KY), said in January that he was preparing to confront FDA over their failure to enact regulations for hemp-derived products like CBD.
Yellen says banks need herb money to help bail them out so 280 banking is soon to be.
Fed Cannabis Legalization Could Provide Boost To Stocks In Second Half Of 2023, Says Bipartisan Panel At SXSW
An Analyst View: How Does Legalization Affect US Cannabis Stocks?
Cantor Fitzgerald's Pablo Zuanic says the lack of progress on the scheduling review of cannabis and the number of states legalizing recreational marijuana "will increase pressure on AG Garland to finally outline the DOJ’s 'marijuana policy' in what could likely be a 2nd version of the Obama administration's Cole Memorandum."
In the analyst's view, "CL2 could have significant implications for the industry, as it could lead to the uplifting of US cannabis stocks and bring in more financial services firms to the industry.”
https://www.benzinga.com/markets/cannabis/23/03/31348482/fed-cannabis-legalization-could-provide-boost-to-stocks-in-second-half-of-2023-says-bipartisan-p
UN Suggests U.S. Federal Government Must Force States To Repeal Marijuana Legalization To Comply With International Treaty.
https://www.marijuanamoment.net/un-suggests-u-s-federal-government-must-force-states-to-repeal-marijuana-legalization-to-comply-with-international-treaty/
Price will be what when?
19MAR2020 TCNNF price $2.33
18MAR2021 the price is 53.73
Today 10MAR 2023 is at 6.00
20APR2024 price will be what? on this when of 420 day. Skipped the year 22
Trulieve Cannabis Corp. (OTC:TCNNF) has a wide variety of brands comprising Alchemy, Avenue, Co2lors, Cultivar, Loveli, Modern Fever, Momenta, Muse, Roll One, Sweet Talk, and Trekkers. Furthermore, the company has various brand partners onboard as well. Trulieve Cannabis Corp. (OTC:TCNNF) has a strong e-commerce presence and sells its cannabis and CBD products through 180 cannabis dispensaries. On February 8, analyst Andrew Partheniou at Stifel assigned Trulieve Cannabis Corp. (OTC:TCNNF) stock a price target of C$34 ($25) and kept a Buy rating on the stock.
https://www.insidermonkey.com/blog/5-most-profitable-pot-stocks-now-1127516/
Twitter becomes first major social platform to allow weed ads
Mainstream advertising platforms have been reluctant to serve a federally illegal industry, in part due to concerns about existing advertisers not wanting to be positioned next to cannabis ads.
So who will be next? Fox news? CBS? heck no they are run by those who do not approve of the devils lettuce along with all thats on tv or the internet. Yahoo runs no adds nor facebook all a bunch of drinkers in charge of America.
https://www.politico.com/news/2023/02/15/twitter-weed-ads-elon-musk-00083026
The FDA approves everything but the herb cause the fda is run by the biggest drug cartel in the world which is big pharma itself.
The FDA understands that there is increasing interest in the potential utility of cannabis for a variety of medical conditions, as well as research on the potential adverse health effects from use of cannabis.
To date, the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition. The agency has, however, approved one cannabis-derived drug product: Epidiolex (cannabidiol), and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). These approved drug products are only available with a prescription from a licensed healthcare provider. Importantly, the FDA has not approved any other cannabis, cannabis-derived, or cannabidiol (CBD) products currently available on the market.
https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process
Here is something about Texas most dont know from 1973 on LBJ birthday..
How the New Drug Law Was Made
Texas' new controlled substances act regulates everything from pot and heroin to those tranquilizers in your pocket.
TEXAS, THE NEXT-TO-LAST state to treat all marijuana possession as a felony (and the last to take seriously its two-years-to-life penalty) quietly succumbed to the ebbing wave of the Sixties counterculture on August 27 as the Texas Controlled Substances Act went into effect. The event was duly commemorated by connoisseurs of the forbidden hemp at midnight celebrations in the privacy of homes across the state—celebrations tempered by the knowledge that even the “reform” law viewed them as deserving a few days or months behind the bars of their nearby county jail, and tempered, too, by a theatrical sense of the absurd that so much energy could have been expended by so many to pass/toughen/ moderate/repeal/amend/reform a Prohibition that was honored more in the breach than the observance. Connoisseurs of irony took note that this particular message-in-a-bottle was lifted from the sand on precisely that day which the more doctrinaire members of the counterculture would once have deemed most piquantly repugnant— Lyndon Baines Johnson’s birthday, a new state holiday. Sic transit gloria psychedelia.
THE LAW WAS PASSED BECAUSE TOO many of the wrong kids were being arrested. The story is really as simple as that. True, before the Legislature finally approved HB 447 a scant five hours before the 63rd session was gavelled to a close on the 28th day of May, the Capitol’s chambers and committee rooms had been the stage for much soul-searching, courage, foolishness, and villainy. But none of this would have happened had not marijuana jumped the tracks from the barrios and black neighborhoods to River Oaks, Highland Park, and Alamo Heights. The police in hot pursuit did not stop to notice that the rules were supposed to change too.
https://www.texasmonthly.com/news-politics/how-the-new-drug-law-was-made/
Or at least direct them all to fill bottles with urine to test for whats all on the federal controlled substance list and then when pop positive throw all in cages.
Be just if Congress were made to be front and center of Jesse, dictating to them whats what with the cannabis plant, the law now changed to legal, but no congress likes alcohol and pills and prisons.
Oxford study to trial cannabis-based medicine as treatment for psychosis
CBD is currently only prescribed for a small number of conditions such as rare, severe epilepsy.
Oxford scientists are to launch a major global trial to investigate whether cannabis-based medicine can treat people with psychosis or psychotic symptoms.
Currently, cannabidiol (CBD) is only prescribed for a small number of conditions. In the UK, for example, these include rare, severe epilepsy, and vomiting or nausea caused by chemotherapy.
The international study will involve 35 centres, mainly in Europe and North America. It will be coordinated by the University of Oxford’s department of psychiatry, which has been awarded £16.5m by the charitable foundation Wellcome.
“Cannabidiol is one of the most promising new treatments for people with psychosis,” said Oxford’s Prof Philip McGuire, who is leading the trial. “Many people with psychosis are open to trying cannabidiol and previous smaller-scale studies have indicated that it has beneficial effects.”
CBD is one of the chemicals found in marijuana but it does not contain tetrahydrocannabinol (THC), the ingredient in marijuana which produces a feeling of intoxication.
The stratification and treatment in early psychosis (Step) programme will involve 1,000 people, including those at clinically high risk of psychosis, people with a first episode of psychosis and patients with psychosis who have not responded to conventional treatment.
https://www.theguardian.com/society/2023/feb/16/global-oxford-study-trial-cannabis-based-medicine-treatment-psychosis-cbd
What about the white market? The legal market.
This ruling sets the example of a good ruling. Out of control blacked out drunks are allowed. That being true anyone deaf blind or mute or even a pot head should be able to own guns.
Ia written in english plain language. Comprehension is difficult to translate into words. Read again and ponder for few too many what post is saying without saying.
They are tied. Why is it blacked out from alcohol humans can hold gun licenses while those that smoke herb who never get double vision or slurred speech cannot have one?
Is because all the law makers are drinkers and condone all the harms associated with.
The Unfulfilled Promise of Cannabis for Cancer-Related Symptoms
— Medical cannabis is currently too far removed from the standards of medical practice
by Marcin Chwistek, MD January 14, 2023
There is a stark contrast between the excitement and promise surrounding the therapeutic use of cannabis -- defined here as any product derived from the plant Cannabis sativa, such as tetrahydrocannabinol (THC) or cannabidiol (CBD) or others -- and its clinical application for cancer patients seeking relief from their symptoms.
Pain, nausea, anxiety, lack of appetite, fatigue, or poor sleep plague many patientsopens in a new tab or window; they often overlap, and frequently persist. As a result, there is an enormous need and interest in finding new and effective ways to treat the symptoms. The available pharmaceutical therapies can help, but many have side effects and are poorly tolerated by some patients.
Many cancer patients (and their clinicians) hoped that medical cannabisopens in a new tab or window would fill that gap. But the results, so far, have been (mostly) disappointing -- both in the published literature and in clinical practice.
This disappointment is especially apparent for the patients with incurable cancer. A few reasons stand out. First, the current process -- a result of persisting dichotomy between the state and federal laws -- practically limits clinicians' involvement in medical cannabis management to only the issuance of medical certifications. It mostly leaves the specific product, dose, and often the route of administration to the dispensaries and patients (there are some differences between states, but this is true for most).
As one of my patients put it (half-jokingly): "You may have this thing around your neck," he said, pointing to my stethoscope, "...but when I go to the dispensary, I am the doc!"
He is one of the few who have been using cannabis for decades and is familiar with its effects. But most patients with advanced cancer are not. Many are elderly and frail, take multiple medications, and receive toxic chemotherapy. They are often overwhelmed by challenges related to a life-threatening illness, and do not have the resilience and patience necessary to navigate a system that is not patient-centered.
Medical cannabis may have the "medical" in its name, but it is far removed from the standards of medical practice. A common clinical scenario is patients trying various cannabis-derived products, usually as an add-on to their established pharmacological regimens, at varying doses for multiple symptoms and usually for brief periods, with minimal supervision or medical advice.
Leaving the process of selecting, dosing, and taking medical cannabis almost entirely in the hands of patients is not fair to them or their caregivers.
"I tried it once, but it didn't work."
"I took it, felt 'out of it,' and stopped."
"My anxiety got worse."
"It might have helped a little, but I cannot afford it."
This is what I hear most often from patients during follow-up visits.
And yet, the underlying irony is that most patients who stopped using it could still potentially benefit from medical cannabis with proper guidance and a process that makes the application of medical cannabis more patient-centered.
The education gap is another reason the current process needs to be revised. For example, in this surveyopens in a new tab or window, only 30% of oncologists said they were comfortable advising patients about cannabis. Yet, two-thirds felt cannabis was helpful as an additional treatment for pain or lack of appetite. Dispensaries are obligated to have a pharmacist or a clinician on staff. Yet, even the most knowledgeable pharmacists can only provide limited guidance as they cannot access the patient's records (except the principal diagnosis) or an accurate list of medications.
Despite many published studies related to the therapeutic application of cannabis, there are only a few that can guide clinicians in practice. This studyopens in a new tab or window is an example of research examining the effects of CBD on a range of symptoms in patients with cancer receiving specialist palliative care. CBD was chosen as it is widely available, does not have the psychomimetic effects of THC, and has shown therapeutic potentialopens in a new tab or window, making it an attractive agent for patients with advanced cancer. And yet, the study failed to showopens in a new tab or window any significant difference between the placebo and CBD groups after 14 days.
Surprising?
As with any clinical trial, one needs to consider the context of the study. For example, the patients included in the study were receiving specialist palliative care (i.e., already getting pain medications, anti-anxiety medications, antidepressants, anti-nausea, and other specific therapeutics). How likely is it that adding CBD daily on top of all these other medications would be powerful enough to show the difference in 2 weeks?
CBD's pharmacology is very complex. In contrast to THC, CBD does not work through the cannabinoid receptors but rather through multiple molecular targets. This likely requires time. It may also be true that CBD could be effective as an alternative to, for example, anti-anxiety medications, but this study was not set up to answer this question. Alternatively, another explanation is that CBD's role for patients with advanced disease and heavy symptom burden is indeed limited. Yet, based on this study, all a practicing physician can gather is that adding it for a short period in a cancer patient with multiple symptoms, who is receiving palliative care, is unlikely to help. We desperately need more well-conducted research that can inform clinical practice.
I believe that medical cannabis has the potentialopens in a new tab or window to help many cancer patients. However, for this to happen, a lot needs to change.
We need better education for clinicians, patients, and caregivers. The knowledge base related to medical cannabis is vast and growing. Cannabis can be helpful, but its use is not without risksopens in a new tab or window. We need standardized products that are carefully labeledopens in a new tab or window, high-quality, free of contaminants, and readily available to patients. In addition, we need robust research conducted in specific patient populations.
But mostly, we need to bring the discussions about cannabis use and benefits back to clinic rooms while forging new relationships with the industry that will allow us to think about medical cannabis in a new innovative way that is vastly different from its recreational applications. Only then can we find ways to incorporate it into the treatment of cancer-related symptoms effectively and safely.
Marcin Chwistek, MD,opens in a new tab or window is a supportive care and palliative medicine specialist at Fox Chase Cancer Center in Philadelphia.
https://www.medpagetoday.com/opinion/second-opinions/102630
Nothing made them wait to sell. Is addictive. Can't get enough of it. Tax loss selling recommenced the first week of jan 2013. Fifty one weeks left.
Short interest is 1.9 million shares. Market cap is $4.9 million. Whats this say?
No wonder on that alcohol and happy new year to the board. Let there be Peace on Herb at least. There will never be peace on earth. But no those in charge say for 5 decades it has been probably longer some states outlawed back a hundred years ago.
Go to war but ya cant have any weed just alcohol.
Drink alcohol as a soldier in the army this happens, get to hang out with fat little puppies. Use herb might get out alive. https://www.reddit.com/r/RussiaUkraineWar2022/comments/tpn0o9/oh_my_lord_russian_soldier_eaten_to_the_bone_by/
Republican governors rejecting a new White House call to pardon low-level marijuana offenders have raked in big campaign donations from the private prison industry that has a financial interest in continuing the drug war.
Biden said he is “calling on governors to pardon simple state marijuana possession offenses.” In response, Republican Govs. Greg Abbott (Texas), Bill Lee (Tenn.) and Asa Hutchinson (Ark.) issued statements brushing off the request.
Those three governors have raked in more than $263,000 from donors linked to the private prison industry, which profits off tough-on-crime policies and incarceration. In all, the private prison industry has funneled more than $1 million into state elections in the last 4 years, mostly to Republicans.
Additionally, since 2020, two private prison giants alone — CoreCivic and the GEO Group — have dumped more than $1.7 million into the Republican Governors Association which bankrolls GOP gubernatorial campaigns across the country. Meanwhile, the industry has spent more than $8.5 million on state lobbying in the last three years.
Thats the million dollar question that few here can answer but the future.
In the present there is this;
https://www.youtube.com/shorts/R7ZTHnp6ZEs
Good for you and many others.
2. Trulieve Cannabis: Florida's top player
With over 120 dispensaries in Florida alone, Trulieve Cannabis is a dominant cannabis player in the state. Investors worried that Trulieve's strategy of concentrating its efforts solely on the state market might be a bad idea. However, this has worked in the company's favor. In the past, the company has been profitable simply by establishing a strong presence in its home state. Trulieve can be profitable again now that it has 178 stores in 11 states.
Despite a 34% increase in revenue to $301 million year over year, the company recorded a net loss of $115 million in the third quarter of 2022. Management attributed this loss to the closure of dispensaries in California and some wholesale operations in Nevada.
The company ended the quarter with $114 million in cash and is continuing to aggressively expand. It anticipates full-year revenue in the $1.25 billion to $1.30 billion range. If the upper end of the guidance is met, it would represent a 39% increase year over year.
https://www.barchart.com/story/news/12755281/down-70-2-growth-stocks-are-smart-buys-in-a-bear-market
Trulieve is also working to get recreational marijuana legalized in Florida. The Miami Times reports that Trulieve spent a total of $15 million on a 2024 recreational cannabis ballot initiative that launched in August. If approved, this initiative will allow medical cannabis dispensaries in the state to sell recreational products.
The legalization of marijuana in Florida will be extremely beneficial to Trulieve, the state's dominant player. Cresco also operates 20 dispensaries across the state. When its acquisition of Columbia Care is completed, Cresco's portfolio will include Columbia Care's 14 dispensaries in the state.
Wrong answer, here is the deal from 5 days ago;
Trulieve Cannabis
A fourth top-notch growth stock you'll regret not buying as the Nasdaq drops into a bear market is U.S. marijuana stock Trulieve Cannabis (OTC:TCNNF). A lack of federal cannabis reform progress on Capitol Hill shouldn't keep opportunistic investors away from a pot stock with a working blueprint.
The most interesting thing about Trulieve has unquestionably been its expansion. Most multistate operators (MSOs) chose to open a couple of dispensaries in as many high-dollar legalized markets as possible. Meanwhile, Trulieve Cannabis focused almost all of its attention on building up its presence in Florida, where medical marijuana is legal, until the midpoint of 2021.
As of the end of November, Trulieve had 180 operating dispensaries, 122 of which were located in the Sunshine State. That's nearly a quarter of the 493 approved dispensaries in the entire state of Florida. Saturating the Sunshine State has allowed the company to effectively build up its brands and awareness without having to spend big on marketing. The result is 19 consecutive quarters (almost five full years) of adjusted profitability.
The next step for Trulieve is to use its successful blueprint in other markets. In October 2021, it completed the acquisition of MSO Harvest Health & Recreation. This deal launched Trulieve into pole position in Arizona, which legalized adult-use weed in November 2020 and commenced retail sales two months later. With a leading presence in two billion-dollar markets and operations growing in a number of other high-dollar states, Trulieve Cannabis looks like a bargain.
https://www.barchart.com/story/news/12775334/nasdaq-bear-market-5-exceptional-growth-stocks-youll-regret-not-buying-on-the-dip